Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

Published:2014-11-30 Issue:1 Volume:172 Page:244-252
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Gniadecki R.¹,Bang B.¹,Bryld L.E.²,Iversen L.³,Lasthein S.⁴,Skov L.⁵

Affiliation:

1. Department of Dermatology; Bispebjerg Hospital; Bispebjerg Denmark

2. Department of Dermatology Roskilde Hospital; University of Copenhagen; Copenhagen Denmark

3. Department of Dermatology; Marselisborg Hospital; Aarhus University; Aarhus Denmark

4. Department of Dermatology; Odense Hospital; University of Southern Denmark; Odense Denmark

5. Department of Dermatology Gentofte Hospital; University of Copenhagen; Copenhagen Denmark

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.13343/fullpdf

Reference22 articles.

1. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data;Rustin;Br J Dermatol,2012

2. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL;Gordon;J Am Acad Dermatol,2012

3. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population;Papp;J Am Acad Dermatol,2010

4. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years;Kimball;Br J Dermatol,2012

5. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris;Gniadecki;Br J Dermatol,2011

Cited by 253 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO);Acta Dermato-Venereologica;2024-09-05

2. Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network;Rheumatology International;2024-08-13

3. Real‐world safety and efficacy of biologics in elderly patients with psoriasis: A multicenter observational study;The Journal of Dermatology;2024-07-19

4. Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, Romania;Psoriasis: Targets and Therapy;2024-06

5. Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database;Frontiers in Immunology;2024-05-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3